PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR

Registros relacionados

• Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
  por: Katsuhiro Yoshimura, MD, et al.
  Publicado em: (2017-01-01)
• Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
  por: Isla D, et al.
  Publicado em: (2016-12-01)
• Phase II trial of second-line erlotinib and digoxin for nonsmall cell lung cancer (NSCLC)
  por: Fadi Kayali, et al.
  Publicado em: (2011-02-01)
• Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
  por: S. V. Orlov, et al.
  Publicado em: (2019-06-01)
• The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
  por: Albina Kibirova, et al.
  Publicado em: (2019-10-01)